Lilly's Abemaciclib Hit Leaves It Down But Not Out
Executive Summary
Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.
You may also be interested in...
Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?
Lilly reported positive top-line results for abemaciclib in the Phase III MONARCH 2 trial and revealed a regulatory strategy that has it rapidly racing after competing CDK4/6 inhibitors already approved for certain breast cancer patients.
Ibrance Trial Cements CDK4/6 Inhibitors As Standard Of Care In Breast Cancer
New England Journal of Medicine editorial sings the praises of CDK4/6 inhibitors in breast cancer, which include Pfizer's Ibrance, Novartis's ribociclib and Elli Lilly's abemaciclib.
Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
Novartis' Phase III MONALEESA-2 trial shows that ribociclib plus letrozole has strong efficacy and an acceptable tolerability profile for first-line advanced HR+/HER2- breast cancer patients, but analysts say the results do not surpass those of Pfizer's first-to-market Ibrance plus letrozole in a similar setting.